Key Word(s): 1. Korean propolis; 2. Helicobacter pylori Presenting Author: JAE JIN HWANG Additional Authors: DONG HO LEE, AE RA LEE, YONG HWAN KWON, YEON SANG JEONG, HYUN JOO LEE, KI CHUL YOON, HYO YOUNG KIM, RYOUNG HEE NAM, HYUK YOON, CHEOL MIN SHIN, YOUNG http://www.selleckchem.com/products/GDC-0449.html SOO PARK, NAYOUNG KIM, YOON JUN KIM Corresponding Author: JAE JIN HWANG Affiliations: Seoul National University Bundang Hospital, Seoul National University Bundang Hospital, Seoul National University Bundang Hospital, Seoul National University Bundang Hospital, Seoul National University Bundang Hospital, Seoul National University Bundang Hospital, Seoul National University Bundang Hospital, Seoul National University Bundang Hospital, Seoul National University

Bundang Hospital,Seoul National University Bundang Hospital, Seoul National University Bundang Hospital, Seoul National University Bundang Hospital, Seoul National University College of Medicine Objective: The http://www.selleckchem.com/products/VX-765.html eradication rate of first and second-line therapies have been decreasing progressively due to increasing antimicrobial resistance of Helicobacter pylori. After two or more consecutive H. pylori eradication failures, clinicians have faced the dilemma of determining which

of the following therapy would be the most appropriate. The aim of this study was to elucidate clinical course and treatment strategies of refractory H. pylori infection. Methods: From 2003 to 2013, total 154 (mean age 62.0: male 75, female 79) patients who had experienced at least two consecutive H. pylori eradication failures were enrolled at

the Seoul National University Bundang Hospital. Efficacy of different MCE rescue regimens was compared by confirming of eradication rate. H. pylori status was evaluated by histologic finding, Campylobacter-like organism test and 13-C urea breath test. Antibiotic susceptibility test for H. pylori was not done in all cases. Results: The clinical and endoscopic findings were as follows : 79 patients (51.3%) had erosive or atrophic gastritis and functional dyspepsia, 21 patients (13.7%) – gastric ulcer (GU), 25 patients (16.2%) – duodenal ulcer (DU), 15 patients (9.7%) – GU + DU, 14 patients – other findings (8 Tubular adenoma, 5 Gastric adenocarcinoma, 1 MALT lymphoma). There was no significant difference in the eradication rate between each rescue regimens. H. pylori eradication rates with the 3 rd, 4th and 5th-line rescue regimens were 53.9% (83/154), 41.2% (21/51), and 26.3% (5/19), respectively. Finally, cumulative H. pylori eradication rate with the 3∼7 th rescue regimens (mean 3.51 times) was 78.7% (111/141). The cumulative incidence rate of gastric cancers did not differ between the eradicated group and failed group (mean observation period: 39.1 months). Conclusion: Even with the consecutive treatments of refractory H. pylori infection using empirical regimens, H. pylori eradication rate was gradually declining. Finally, cumulative overall eradication rate could not achieve over 80%.